Ha Mo Linh Le

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Guy's Hospital, London, UK

PARP inhibitors in metastatic breast cancer with BRCA mutation

Disclosures

Sponsors for congress: Ipsen, Astellas

Oncology History (1)

- 54 year-old post menopausal woman
- No significant PMH, family history of cancer (lung, colon, ovarian, prostate cancers)
- January 2017: diagnosed with right breast cancer
- Underwent wide local excision and axillary clearance, 40 mm, LVI positive, nodes 4/15, TNBC, narrow margins < 1 mm, BRCA2 germline mutation
- Adjuvant chemotherapy: accelerated EC x 2 cycles then 3 weekly carboplatin weekly paclitaxel for 12 weeks
- Contra-indication to adjuvant bisphosphonates due to dental issues
- 3/10/17: Right completion mastectomy and risk reducing salpingoophorectomy – Histology: 36mm residual invasive carcinoma, completely excised.
- December 2017: completed adjuvant RT right chest wall and SCF

Oncology History (2)

- January 2018: CT scan shows progressive disease with right internal mammary nodes, mediastinal, right hilar and upper abdominal adenopathy. Skeletal involvement in the manubrium and ribs
- EBUS-TBNA station 7 and 4L: metastatic adenocarcinoma with new right pleural effusion. ER, PR, HER-2 negative. Bone scan negative
- February 2018: patient admitted for pleural drain due to symptomatic pleural effusion. Vocal cord palsy due to laryngeal nerve involvement. Started carboplatin AUC 6 as an inpatient, received 2 cycles with partial response
- April 2018: received compassionate access to olaparib 300 mg BD in the first line metastatic setting

Radiological response to olaparib

After 3 months of treatment





Tolerance to olaparib and clinical response

- G1 nausea, G1 diarrhoea, No haematological toxicity
- ECOG PS improved from 2 to 1, chest drains removed, bone pain resolved, vocal cord palsy improved

- Litterature: phase III OlympiAD compared olaparib vs standard single agent chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastic breast cancer and a germline *BRCA* mutation.
  - 302 patients randomly assigned
  - median PFS was 7.0 months for patients in the olaparib group compared with 4.2 months for patients in the TPC group (HR 0.58)
  - ORR was 59.9% in the olaparib group, compared with 28.8% in the TPC group
- FDA has granted approval to olaparib in January 2018

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

ESMO Preceptorship Programme